title: [Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen].
abstract: BACKGROUND
  In Mexico the breast cancer occupies the second place as cause of death by oncological illness and the etiology is considered multifactorial. The systemic treatment of this cancer is necessarily after the surgery and simultaneously when radiotherapy is used; therefore the recent introduction of newly non toxics and efficient antiestrogens which block the effect of estrogens from circulation have become drugs of first line in the metastasis illness.
  
  
  OBJECTIVE
  To compare the clinical evolution and the survival of patients with locally advanced breast cancer and metastasis with the use of two therapeutic modalities.
  
  
  METHODS
  Under informed consent 20 patients with diagnosis of breast cancer and out of oncological therapeutic processing were included. Randomly an inhibitor of the aromatase (anastrozole, 1 mg for day) was used in 10 patients and in the other 10 patients tamoxifen (20 mg for day) both for 2 years, subject to verification of positive estrogens-progesterone receptors.
  
  
  RESULTS
  Half of the patients of each group had a clinical stage III. The most frequent histological diagnosis was the ductal carcinoma in 70% of the group with tamoxifen use, while in anastrozole group was 90%; the mastectomy prior to the tamoxifen was carried out in 60% of the patients and in 50% of the group with anastrozole. The acceptable response to the processing in the patients with tamoxifen was complete in the 60% of the cases, but with the use of anastrozole was 80%; survival in the group with anastrozole was of 100% in two years of follow up, while in women that received tamoxifen the survival was 90% (p<0.001).
  
  
  CONCLUSIONS
  The use of anastrozole improved the survival as well as the quality of life, showing no side effects in this group of patients.
authors.affiliation: Servicio de oncología, Hospital de Gineco-Obstetricia núm 3, Centro Médico La Raza y Unidad de Investigación Médica en Enfermedades Endocrinas, Centro Médico Nacional, Instituto Mexicano del Seguro Social.
authors.forename: Germán
authors.initials: G
authors.lastname: Castelazo Rico
authors.forename: Donaji
authors.initials: D
authors.lastname: Molotla Xolalpa
authors.forename: María Antonia
authors.initials: MA
authors.lastname: Basavilvazo Rodríguez
authors.forename: Leobardo
authors.initials: L
authors.lastname: Angeles Victoria
authors.forename: Arturo
authors.initials: A
authors.lastname: Zárate
authors.forename: Marcelino
authors.initials: M
authors.lastname: Hernández Valencia
mesh_terms: D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D005260:Female; D006801:Humans; D009570:Nitriles / Q000627:therapeutic use*; D011446:Prospective Studies; D015996:Survival Rate; D013629:Tamoxifen / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole